𝐂𝐚𝐫𝐜𝐢𝐧𝐨𝐢𝐝 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 𝐃𝐢𝐚𝐫𝐫𝐡𝐞𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝟐𝟎𝟏𝟖 - 𝟐𝟎𝟐𝟔 | 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢�

Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations, menopause, irritable bowel disease, and asthma. For instance, in 2009, a study by Journal of Clinical Oncology, showed 4 to 5 out of every 100,000 people are diagnosed with a neuroendocrine tumor and over 100,000 people suffering from neuroendocrine tumor in the U.S., also most individual suffering from carcinoid are asymptomatic until the tumor is fully developed. To overcome the carcinoid crisis, treatment options may considered such as surgery, chemotherapy, targeted radionuclide therapy, radiofrequency ablation, and chemoembolization on the basis of patient-by-patient. Carcinoid syndrome being a rare condition, there are very few if any treatment options available. This in turn, creates a highly lucrative opportunities for market players.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐎𝐟 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.coherentmarketinsights.com/insight/request-pdf/1216

𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐚𝐫𝐜𝐢𝐧𝐨𝐢𝐝 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 𝐃𝐢𝐚𝐫𝐫𝐡𝐞𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐚𝐱𝐨𝐧𝐨𝐦𝐲:

By Treatment Type:
• Chemotherapy
• Oral Therapy
• Somatostatin Analog (SSA) Therapy
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

𝐍𝐨𝐯𝐞𝐥 𝐠𝐫𝐨𝐮𝐧𝐝-𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐨 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐢𝐦𝐦𝐞𝐧𝐬𝐞 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐟𝐨𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡

In February 2017, Lexicon Pharmaceutical Inc., announced that the U.S. Food and Drug Administration (FDA) approved Xermelo (Telotristat etiprate) as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy (SSA) for adults. Xermelo mainly targets the overproduction of serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea. Furthermore, in 2017, Ipsen Biopharmaceutical, announced the U.S. Food and Drug Administration (FDA) approval for a supplemental indication of Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of short-acting somatostatin analogue rescue therapy.

Development of first-of-its-kind therapeutic approach to treat carcinoid syndrome diarrhea creates highly lucrative growth opportunities for market players. However, low awareness and certain side effects associated with this therapy are expected to hinder growth of the carcinoid syndrome diarrhea treatment market.

𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐩𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐫𝐚𝐫𝐞 𝐜𝐚𝐫𝐜𝐢𝐧𝐨𝐢𝐝 𝐬𝐲𝐧𝐝𝐫𝐨𝐦𝐞 𝐝𝐢𝐚𝐫𝐫𝐡𝐞𝐚 𝐭𝐨 𝐛𝐨𝐨𝐬𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡

According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome diarrhea treatment devices. This in turn is expected to fuel growth of the carcinoid syndrome diarrhea treatment market.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/ongoing-insight/carcinoid-syndrome-diarrhea-treatment-market-1216

𝐌𝐚𝐣𝐨𝐫 𝐤𝐞𝐲 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐚𝐫𝐜𝐢𝐧𝐨𝐢𝐝 𝐬𝐲𝐧𝐝𝐫𝐨𝐦𝐞 𝐝𝐢𝐚𝐫𝐫𝐡𝐞𝐚 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 𝐋𝐞𝐱𝐢𝐜𝐨𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬, 𝐈𝐧𝐜., 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐆 (𝐒𝐚𝐧𝐝𝐨𝐳), 𝐏𝐡𝐚𝐫𝐦𝐚𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐈𝐧𝐜., 𝐎𝐦𝐞𝐠𝐚 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐢𝐞𝐬 𝐋𝐭𝐝., 𝐓𝐞𝐯𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐢𝐞𝐬 𝐋𝐭𝐝., 𝐌𝐲𝐥𝐚𝐧 𝐍.𝐕., 𝐈𝐩𝐬𝐞𝐧 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬, 𝐈𝐧𝐜., 𝐒𝐢𝐫𝐭𝐞𝐱 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐋𝐢𝐦𝐢𝐭𝐞𝐝, 𝐚𝐧𝐝 𝐁𝐓𝐆 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐋𝐭𝐝.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
𝐄𝐦𝐚𝐢𝐥: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.